Loading...

PE Streptavidin

Pricing & Availability
Regulatory Status
RUO
Other Names
Streptavidin-Phycoerythrin, SAv-PE
Ave. Rating
Submit a Review
Product Citations
publications
SAV_PE_082808.jpg
C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
  • SAV_PE_082808.jpg
    C57BL/6 splenocytes stained with 145-2C11 biotin, followed by SAV-PE
See PE spectral data
Cat # Size Price Quantity Check Availability Save
405203 100 µg 56 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
405204 500 µg 195 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

Streptavidin binds to biotin with high affinity. Streptavidin-Phycoerythrin (PE) is useful for detecting biotinylated antibodies. The excitation of PE by 488 nm laser light induces a light emission maximum of 575 nm.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Human, Mouse, Rat, All Species
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
Streptavidin is conjugated with PE under optimal conditions.
Concentration
0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling
The streptavidin-PE solution should be stored undiluted between 2°C and 8°C, and protected from exposure to light. Do not freeze.
Application

FC - Quality tested

ICFC - Verified
Recommended Usage

This streptavidin product is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the PE conjugation. For flow cytometric staining, the suggested use of this reagent is ≤0.06 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes

Streptavidin-Phycoerythrin (PE) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-PE is 360 kD and Streptavidin alone is 52 kD.

Application References

(PubMed link indicates BioLegend citation)
  1. Chappaz S, et al. 2007. Blood doi:10.1182/blood-2007-02-074245.
  2. Nishimoto KP,et al. 2008. J. Immunol. 181:4010.PubMed
  3. Niki T, et al. 2009. J. Biol. Chem. 284:32344. PubMed
  4. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed
  5. Scatizzi JC, et al. 2012. J. Immunol. 188:3307. PubMed
  6. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  7. Shibata T, et al. 2012. Int Immunol. 24:613. PubMed
  8. Baccala R, et al. 2012. J. Immunol. 189:5976. PubMed
  9. Grevers LC, et al. 2013. Ann Reheum Dis. 72:278. PubMed
  10. Woo SJ, et al. 2013. J Leukoc Biol. 93:363. PubMed
  11. Ashbaugh JJ, et al. 2013. J. Immunol. 190:4525. PubMed
  12. Reading JL, 2013. J. immunol. 190:4542. Pubmed.
  13. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  14. Gunaydin G, et al. 2014. Vaccine. 32:470. PubMed
  15. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. He X, et al. 2014. J Immunol. 193:1314. PubMed
  18. Wang W, et al. 2014. PNAS. 111:14466. PubMed
  19. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  20. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  21. Kim Yu, et al. 2015. PLoS One. 10:120294. PubMed
  22. Hua X, et al. 2015. PloS One. 10:128039. PubMed
Product Citations
  1. Zhang Y, et al. 2017. Journal of Immunological Methods. 10.1016/j.taap.2017.05.020. PubMed
  2. Wang H, et al. 2020. Mol Oncol. 14:991. PubMed
  3. Martínez-Blanco Á, et al. 2021. Front Immunol. 12:713697. PubMed
  4. Eger C, et al. 2016. PLoS One. 11: 0150479. PubMed
  5. Yang J, et al. 2016. Sci Rep. 6:38238. PubMed
  6. Chen T, et al. 2016. J Exp Med. 13(13):3025-3039. PubMed
  7. Lv X, et al. 2022. Acta Pharm Sin B. 12:735. PubMed
  8. Muliaditan T, et al. 2021. Cell Rep Med. 2:100457. PubMed
  9. Tian L, et al. 2021. Int J Mol Sci. 22: . PubMed
  10. Delás MJ, et al. 2019. Cell Rep. 27:719. PubMed
  11. Viborg N, et al. 2019. Oncoimmunology. 8:e1663107. PubMed
  12. Trendel N, et al. 2021. Sci Signal. 14:eaay9363. PubMed
  13. Gatineau J, et al. 2022. Front Immunol. 13:982839. PubMed
  14. Yamakawa N, et al. 2012. Int Immunol. 25:45. PubMed
  15. Grevers L, et al. 2013. Ann Rheum Dis. 72:278. PubMed
  16. Datta S, et al. 2014. J Leukoc Biol. 95:853. PubMed
  17. Larsen SB, et al. 2021. Cell Stem Cell. 28:1758. PubMed
  18. Ruiz–Camp J, et al. 2019. EMBO Mol Med. 11:3. PubMed
  19. Nie X, et al. 2017. Cellular & Molecular Immunology. 10.1038/cmi.2017.17. PubMed
  20. Hernandez-Franco JF, et al. 2022. Front Immunol. 13:990900. PubMed
  21. Liang Q, et al. 2022. iScience. 25:104043. PubMed
  22. Xiao C, et al. 2022. iScience. 25:103934. PubMed
  23. Imbrechts M, et al. 2022. iScience. 25:104705. PubMed
  24. Biswas S, et al. 2021. Nature. 591:464. PubMed
  25. Wellner A, et al. 2021. Nat Chem Biol. 17:1057. PubMed
  26. Gniffke EP, et al. 2020. medRxiv. . PubMed
  27. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  28. Fukushima T, et al. 2019. Cell Rep. 29:4144. PubMed
  29. Hu Y, et al. 2022. Nat Commun. 13:5313. PubMed
  30. Ashbaugh J, et al. 2013. J Immunol. 190:4525. PubMed
  31. Kim Y, et al. 2015. PLoS One. 10:120294. PubMed
  32. Yamamoto K, et al. 2021. Cell Reports. 36(8):109576. PubMed
  33. Nishimoto K, et al. 2008. J Immunol. 181:4010. PubMed
  34. Cao Y, et al. 2022. Nature. :. PubMed
  35. He X, et al. 2021. Emerg Microbes Infect. 10:1555. PubMed
  36. Im S, et al. 2016. Nature. 537:417-421. PubMed
  37. Schanda N, et al. 2021. Cells. 10:. PubMed
  38. Tsukamoto H, et al. 2013. Biochem Biophys Res Commun. 440:31. PubMed
  39. Phiwpan K, et al. 2015. PLoS One. 10:128198. PubMed
  40. Weiß S, et al. 2020. J Infect Dis. 222:1629. PubMed
  41. Niki T, et al. 2009. J Biol Chem. 284:32344. PubMed
  42. Ping Y, et al. 2020. Front Cell Dev Biol. 0.890972222. PubMed
  43. Lv Z, et al. 2020. Oncoimmunology. 9:1747688. PubMed
  44. Pfenninger P, et al. 2022. Front Immunol. 13:777113. PubMed
  45. Kristensen NP, et al. 2022. J Clin Invest. 132:. PubMed
  46. Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed
  47. Cao Y, et al. 2022. Nature. 602:657. PubMed
  48. Rogers BM, et al. 2021. J Exp Med. 218:. PubMed
  49. Köchl R, et al. 2020. Elife. 9:00. PubMed
  50. Lucas A, et al. 2015. PLoS One. 10:117160. PubMed
  51. Dietmar Herndler‐Brandstetter et al. 2018. Immunity. 48(4):716-729 . PubMed
  52. Kim C, et al. 2019. Cell Rep. 29:2202. PubMed
  53. Hansen UK, et al. 2020. Front Immunol. 11:373. PubMed
  54. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
  55. Mei H, et al. 2021. J Hematol Oncol. 14:161. PubMed
  56. Repáraz D, et al. 2022. J Immunother Cancer. 10:. PubMed
  57. Reading J, et al. 2013. J Immunol. 190:4542. PubMed
  58. Weiß S, et al. 2020. medRxiv. . PubMed
  59. Hebbar N, et al. 2022. Nat Commun. 13:587. PubMed
  60. Tschismarov R, et al. 2021. JCI Insight. 6:. PubMed
  61. Richardson LS, et al. 2020. Lab Chip. 3.948611111. PubMed
  62. Van Gool F, et al. 2019. Immunity. 50:362. PubMed
  63. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
  64. McWilliam H, et al. 2016. Nat Immunol. 17: 531-537. PubMed
  65. Zhang S, et al. 2016. Sci Transl Med. 8: 341ra77. PubMed
  66. Delacher M, et al. 2020. Immunity. 52:295. PubMed
  67. Tsukamoto H, et al. 2017. FEBS Lett. 10.1002/1873-3468.12768. PubMed
  68. Parente-Pereira AC, et al. 2022. STAR Protoc. 3:101319. PubMed
  69. Baltierra-Uribe SL, et al. 2021. Eur J Immunol. 51:2641. PubMed
  70. Schoutrop E, et al. 2022. Oncoimmunology. 11:2093426. PubMed
  71. Jiang Y, et al. 2021. Cell Death Differ. 28:3009. PubMed
  72. Mainini F, et al. 2015. PLoS One. 10: 0145403. PubMed
  73. Woo S, et al. 2013. J Leukoc Biol. 93:363. PubMed
  74. Baccala R, et al. 2012. J Immunol. 189:5976. PubMed
  75. Tian B, et al. 2017. Front Immunol. 10.3389/fimmu.2017.00956. PubMed
  76. Schoofs T et al. 2019. Immunity. 50(6):1513-1529 . PubMed
  77. Carestia A, et al. 2019. Cell Rep. 28:896. PubMed
  78. Scatizzi J, et al. 2012. J Immunol. 188:3307. PubMed
  79. Guo C, et al. 2021. Cell Rep Med. 2:100448. PubMed
  80. Chen YL, et al. 2021. J Biol Chem. :101420. PubMed
  81. Zhong MC, et al. 2021. J Exp Med. 218:. PubMed
  82. Mudd PA, et al. 2022. Cell. 185:603. PubMed
  83. Günaydın G, et al. 2014. Vaccine. 32:470. PubMed
  84. Matt P, et al. 2015. PLoS One. 10: 0137474. PubMed
  85. Davis Z, et al. 2016. PLoS Pathog. 12: 1005421. PubMed
  86. Roewe J, et al. 2020. Nat Commun. 3.260416667. PubMed
  87. Leung EYL, et al. 2020. Mol Ther Oncolytics. 16:289. PubMed
  88. Nowak W, et al. 2020. EBioMedicine. 50:290-305.. PubMed
  89. Matsuda T, et al. 2022. iScience. 25:105324. PubMed
  90. Kim SP, et al. 2022. Cancer Immunol Res. :OF1. PubMed
  91. Cheloha RW, et al. 2021. RSC chem biol. 2:1692. PubMed
  92. Okamoto Y, et al. 2021. J Cell Sci. 134:. PubMed
  93. Gniffke EP, et al. 2020. J Infect Dis. 222:1965. PubMed
  94. Morikawa M, et al. 2016. PLoS One. 11:e0163607. PubMed
  95. Andersen TK, et al. 2019. NPJ Vaccines. 4:9. PubMed
  96. Lu X, et al. 2019. Cell Rep. 28:472. PubMed
  97. Hoffmann J, et al. 2021. Nat Commun. 12:3964. PubMed
  98. Wang W, et al. 2014. Proc Natl Acad Sci U S A. 111:14466. PubMed
  99. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  100. Leary N, et al. 2022. J Extracell Vesicles. 11:e12197. PubMed
  101. Dan JM, et al. 2021. Science. :371. PubMed
  102. He X, et al. 2014. J Immunol. 193:1314. PubMed
  103. Kanno A, et al. 2013. Int Immunol. 25:413. PubMed
  104. Walker MR, et al. 2022. Sci Adv. 8:eabj9513. PubMed
  105. Yang Zhou J, et al. 2022. Front Immunol. 13:898473. PubMed
  106. Deng J, et al. 2021. J Leukoc Biol. 110:1171. PubMed
  107. Murakami Y, et al. 2014. J Immunol. 193:5208. PubMed
  108. Mchedlidze T, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.20. PubMed
  109. Chappaz S, et al. 2010. J Immunol. 185:3514. PubMed
  110. Altman JB, et al. 2018. Health Sci Rep. 1:e74. PubMed
  111. Hirunwidchayarat W, et al. 2017. Biochem Biophys Res Commun. 10.1016/j.bbrc.2017.07.012. PubMed
  112. Wang EY, et al. 2022. Cell Rep Methods. 2:. PubMed
  113. Kurashima Y, et al. 2021. Nat Commun. 12:1067. PubMed
  114. Wells DK, et al. 2020. Cell. 183:818. PubMed
  115. Schürch CM, et al. 2020. Cell. 182:1341. PubMed
  116. DanDan Huang, Lang Bao 2016. J Microbiol Immunol Infect. 49:859-865. PubMed
  117. Zheng Q, et al. 2017. Mol Oncol. 10.1002/1878-0261.12056. PubMed
  118. Pedersen NW, et al. 2019. Nat Commun. 10:837. PubMed
  119. Yang C, et al. 2019. Nat Commun. 10:3931. PubMed
  120. Xiao C, et al. 2021. STAR Protoc. 2:100789. PubMed
  121. Rodrigues KA, et al. 2021. Sci Adv. 7:eabj6538. PubMed
  122. Szeto C, et al. 2022. Nat Commun. 13:4951. PubMed
  123. Lyngaa R, et al. 2014. Clin Cancer Res. 20:1768. PubMed
  124. Tripathi S, et al. 2016. Proc Natl Acad Sci U S A. 113: 1555 - 1564. PubMed
  125. Ando Y, Oku T, Tsuji T 2016. PLoS One. 11: 0162208. PubMed
  126. Lautz JD, et al. 2019. Sci Rep. 9:10890. PubMed
  127. Kenney M, et al. 2017. Journal of Immunological Methods. 10.1016/j.jim.2017.07.001. PubMed
  128. Wirasinha RC, et al. 2021. J Exp Med. 218: . PubMed
  129. Holm JS, et al. 2022. Nat Commun. 13:1935. PubMed
  130. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
  131. Yoshikawa S, et al. 2016. Sci Rep. 6:18738. PubMed
  132. Shibui A, et al. 2011. Exp Parasitol. 129:318. PubMed

Related FAQs

What type of PE do you use in your conjugates?
We use R-PE in our conjugates.
Go To Top Version: 6    Revision Date: 06.17.2019

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account